Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherLetters to the Editor

Sincalide-Stimulated Cholescintigraphy: What Is the Standard?

Gerbail T. Krishnamurthy and Shakuntala Krishnamurthy
Journal of Nuclear Medicine June 2010, 51 (6) 996; DOI: https://doi.org/10.2967/jnumed.110.076588
Gerbail T. Krishnamurthy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shakuntala Krishnamurthy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

TO THE EDITOR: The article by Ziessman et al. adds to the further understanding of gallbladder physiology and the effect of cholecystokinin (CCK) stimulation (1). They suggest considering a 38% gallbladder ejection fraction (GBEF) as the lower limit of normal for a 0.02 μg/kg infusion of CCK-8 over 60 min and that their method of study should become the standard for routine clinical use. We would like to comment on some limitations inherent in the design, execution, and conclusions of their study that one should take into consideration in determining whether their method should become the standard.

Ziessman et al. chose a Food and Drug Administration–approved CCK-8 dose (0.02 μg/kg to be given over 0.5–1 min) but decided to infuse over 15, 30, or 60 min, thus changing the dose rate at each level. The gallbladder continues to empty during and for 8–12 min after CCK-8 infusion. An accurate measurement of GBEF, therefore, requires that the downward slope of the curve be included in the calculation of GBEF. Drug dose–response studies require that either the dose rate or the duration of infusion be kept constant to test the complete effect of the drug. Because the GBEF does not follow a Gaussian distribution, one cannot use the mean and SD to set the lower limit of the reference range. The mean and wide SD of GBEF values shown in their Table 1 confirm the variability of GBEF seen in healthy subjects. Therefore, one needs to establish the frequency or distribution data to set the lower limit for a normal response. For the gallbladder phase of the study, we collect data at 1 frame/min for 30 min; and beginning at 3 min, CCK-8 is infused at a rate of 3 ng/kg/min for 10 min. A GBEF value below 50% is considered abnormal. Approximately 50% of the patients with chronic acalculous or chronic calculous cholecystitis experience low- to moderate-intensity abdominal pain during or after CCK-8 infusion. The total duration of 90-min data collection allows diagnosis of various types of hepatobiliary and gastrointestinal diseases associated with bile formation and flow (2).

The study designed by Ziessman et al. is much longer (120 min) than our method (90 min), and abrupt termination of CCK-8 data collection at 120 min results in missing the downward slope of the curve in the calculation of an accurate GBEF (2). Paradoxic gallbladder filling seen in sphincter-of-Oddi spasm occurs immediately after termination of the CCK-8 infusion and will be missed if data collection is not continued for an additional 10–15 min. In addition, 60 min of continuous CCK-8 infusion induces bile transit throughout the small intestine, often reaching the colon. This prevents detection of CCK-8–induced intestinal hyperperistalsis indicative of irritable bowel syndrome seen with a shorter CCK-8 infusion. Radiolabeled bile is an excellent tracer not only for measurement of GBEF but also for detection of various other hepatobiliary and gastrointestinal diseases (2). Most patients who experience abdominal pain and discomfort with CCK-8 are likely to prefer a 30-min infusion over 60 min. The suggestion that their method of study should become the standard for routine clinical use may not be very appealing from the patient's point of view.

Footnotes

  • COPYRIGHT © 2010 by the Society of Nuclear Medicine, Inc.

References

  1. 1.↵
    Ziessman HA, Tulchinsky M, Lavely WC, et al. Sincalide-stimulated cholescintigraphy: a multicenter investigation to determine optimal infusion methodology and gallbladder ejection fraction normal values. J Nucl Med. 2010;51:277–281.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Krishnamurthy GT, Krishnamurthy S. Nuclear Hepatology: A Textbook of Hepatobiliary Diseases. 2nd ed. New York, NY: Springer; 2009:299–317.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 51 (6)
Journal of Nuclear Medicine
Vol. 51, Issue 6
June 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Sincalide-Stimulated Cholescintigraphy: What Is the Standard?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Sincalide-Stimulated Cholescintigraphy: What Is the Standard?
Gerbail T. Krishnamurthy, Shakuntala Krishnamurthy
Journal of Nuclear Medicine Jun 2010, 51 (6) 996; DOI: 10.2967/jnumed.110.076588

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Sincalide-Stimulated Cholescintigraphy: What Is the Standard?
Gerbail T. Krishnamurthy, Shakuntala Krishnamurthy
Journal of Nuclear Medicine Jun 2010, 51 (6) 996; DOI: 10.2967/jnumed.110.076588
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Not All Gatekeepers Are Theranostics
  • Reply to: Potential of 188Re as an Alternative to 177Lu and Dosimetric Consequences
  • Reply to: Not All Gatekeepers Are Theranostics
Show more Letters to the Editor

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire